Targeting glycosphingolipid (GSL) synthesis by blocking the rate-limiting enzyme glucosylceramide synthase (GCS) encoded by the gene UDP-glucose-ceramide-glucosyltransferase (UGCG) has been considered as an option in cancer therapy [9,10]. This evidence concerns the gene UGCG and cancer.